RNA targeted therapeutics drugs have shown significant promise in treating various chronic diseases such as cancer and genetic disorders in recent years. These drugs work by interfering with the expression of disease-associated RNAs through mechanisms including degradation, splicing modulation, and translation inhibition. The key therapeutic areas where RNA targeted drugs are being developed and tested include oncology, cardiology, metabolic disorders, and infectious diseases.
The Global RNA Targeted Therapeutics Market is estimated to be valued at US$ 1.34 Bn in 2024 and is expected to exhibit a CAGR of 35% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the RNA Targeted Therapeutics are Abivax,AC Immune,Arrakis Therapeutics,eFFECTOR Therapeutics,Eloxx Pharmaceuticals. These players are developing novel RNA targeted drugs that can selectively block disease-driving transcripts to treat various conditions.
The growing demand for precision medicines with minimal off-target effects is expected to drive the demand for RNA targeted drugs in the coming years. These drugs provide an attractive modality for developing therapies against previously undruggable disease targets such as long non-coding RNAs and microRNAs.
Major pharmaceutical companies are also actively pursuing acquisitions and partnerships in this field to gain access to new RNA targeted assets and expand their global operations. For instance, Roche has partnered with Arrakis to develop RNAi therapies for neurological diseases. Such deals indicate the interest in this evolving field of drug development.
Market key trends
One of the major trends in the RNA targeted therapeutics market is the development of enhanced RNA delivery technologies. Effective delivery of nucleic acid drugs to diseased tissues/organs has been a challenge due to hurdles such as enzymatic degradation, immune surveillance, and poor cellular/subcellular uptake. Recent research efforts are focused on formulating RNA drugs in innovative delivery systems like nanoparticles, exosomes, and conjugates that can shield RNA cargos and facilitate uptake. This is expected to overcome various pharmacokinetic limitations and aid the clinical translation of therapeutic candidates.
Porter’s Analysis
Threat of new entrants: The RNA targeted therapeutics market requires high capital investments and technical skills. This limits the threat of new companies entering the market.
Bargaining power of buyers: Individual consumers have little influence over market prices due to the highly specialized nature of RNA targeted therapeutics technologies. However, large pharmaceutical companies can influence prices by negotiating volume discounts.
Bargaining power of suppliers: Majority of raw material suppliers are large established companies reducing the buyer’s risks of supply shortage. However, their bargaining power is relatively high due to limited alternative supplier options.
Threat of new substitutes: New biologics and gene therapies are emerging rapidly as substitutes. Ease of development and administration of new substitutes increases competitive pressure.
Competitive rivalry: Fierce competition exists among major players to gain technology leadership. Companies compete based on their innovation capabilities in RNA targeting platforms and development pipelines.
Geographical regions
North America currently holds the dominant share in the RNA targeted therapeutics market, mainly due to increasing prevalence of rare genetic disorders and cancer. The United States contributes significantly to the large market size owing to favorable regulatory environment and heavy investments in R&D by biopharma companies.
Asia Pacific is expected to be the fastest growing regional market during the forecast period attributed to rising healthcare spending, growing middle-class population and increasing focus of global players on establishing manufacturing & distribution centers in countries like China and India to cater to the regional demand.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it